Literature DB >> 6188527

Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease.

B Shapiro, M Chakrabarty, E M Cohn, S A Leon.   

Abstract

Previous studies showed that patients with neoplasms of various types and origins have abnormally high concentration of DNA in their serum. The current work compares circulating DNA levels in patients with benign or malignant disease of the gastrointestinal tract and determines the diagnostic value of such measurements. DNA was quantitated by radioimmunoassay capable of detecting 25 ng/ml, and as a simple and noninvasive test, it could be a useful addition to other diagnostic procedures. The GI tract was chosen because it affords a comparison of benign, precancerous, and malignant lesions of the same organ. Of the 386 patients studied prospectively, 48% had benign disease and mean DNA levels (+/- SE) of 118 +/- 14 ng/ml, whereas 52% had malignant disease and 412 +/- 63 ng DNA/ml. The difference was statistically significant (P less than 0.001). The DNA assay showed the highest sensitivity for pancreas carcinoma: 90% of the patients had DNA levels above 100 ng/ml, chosen as the upper normal limit. Simultaneous measurements of both DNA and carcinoembryonic antigen (CEA) resulted in increased sensitivity and specificity, even when either marker alone had low sensitivity (gastric carcinoma). The results indicate that serum DNA concentration is markedly elevated in malignancy, and moderately elevated in benign disease, as compared with normal controls. These findings may have diagnostic and prognostic value.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6188527     DOI: 10.1002/1097-0142(19830601)51:11<2116::aid-cncr2820511127>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  90 in total

1.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

Review 2.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 3.  Nucleic acids in circulation: are they harmful to the host?

Authors:  Indraneel Mittra; Naveen Kumar Nair; Pradyumna Kumar Mishra
Journal:  J Biosci       Date:  2012-06       Impact factor: 1.826

Review 4.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

Authors:  Bert Gold; Milena Cankovic; Larissa V Furtado; Frederick Meier; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2015-05       Impact factor: 5.568

Review 5.  Latest development of liquid biopsy.

Authors:  Alvin Ho-Kwan Cheung; Chit Chow; Ka-Fai To
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 6.  Tumor heterogeneity in the clinic: is it a real problem?

Authors:  Filip Janku
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

7.  Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched.

Authors:  José Miguel García; Vanesa García; Cristina Peña; Gemma Domínguez; Javier Silva; Raquel Diaz; Pablo Espinosa; Maria Jesús Citores; Manuel Collado; Félix Bonilla
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

Review 8.  Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA.

Authors:  Michael D Kessler; Nisha R Pawar; Stuart S Martin; Toni M Antalis; Timothy D O'Connor
Journal:  Trends Cancer       Date:  2018-08-01

9.  EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages.

Authors:  N Mohammed; M Rodriguez; V Garcia; J M Garcia; G Dominguez; C Peña; M Herrera; I Gomez; R Diaz; B Soldevilla; A Herrera; J Silva; F Bonilla
Journal:  Oncol Lett       Date:  2011-04-28       Impact factor: 2.967

10.  DNA methylation in circulating tumour DNA as a biomarker for cancer.

Authors:  Ruth E Board; Lucy Knight; Alastair Greystoke; Fiona H Blackhall; Andrew Hughes; Caroline Dive; Malcolm Ranson
Journal:  Biomark Insights       Date:  2008-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.